Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 3Phase 1/2 2Phase 1 1

Status

Terminated 2Active not recruiting 2Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Neoplasms 2Neoplasm Metastasis 2Pancreatic Neoplasms 1Lung Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 70Nivolumab 36Cyclophosphamide 34Carboplatin 28Dexamethasone 23Specimen Handling 22Paclitaxel 22Lenalidomide 22durvalumab 19Radiotherapy 19Gemcitabine 19venetoclax 18Magnetic Resonance Spectroscopy 18Doxorubicin 17Rituximab 16fludarabine 15Ipilimumab 15Bevacizumab 15Cisplatin 14Biopsy 14atezolizumab 13Etoposide 13Vincristine 12Pemetrexed 12belantamab mafodotin 11Docetaxel 11Calcium Dobesilate 11Azacitidine 11olaparib 10Oxaliplatin 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Active not recruiting × adagrasib × Clear all
NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT05375994 2025-05-18

RAMP204

Verastem, Inc.

Phase 1/2 Active not recruiting
85 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡